Corcept Therapeutics has patented a method for treating antipsychotic-induced weight gain using the cyclohexyl pyrimidine glucocorticoid receptor modulator miricorilant. The method involves administering miricorilant along with antipsychotic medication to reduce, prevent, or reverse weight gain and associated metabolic issues. GlobalData’s report on Corcept Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Corcept Therapeutics Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Corcept Therapeutics, Cancer treatment biomarkers was a key innovation area identified from patents. Corcept Therapeutics's grant share as of February 2024 was 42%. Grant share is based on the ratio of number of grants to total number of patents.

Treating antipsychotic-induced weight gain with miricorilant

Source: United States Patent and Trademark Office (USPTO). Credit: Corcept Therapeutics Inc

A recently granted patent (Publication Number: US11903945B2) discloses a method for treating antipsychotic-induced weight gain in patients by administering a cyclohexyl pyrimidine glucocorticoid receptor modulator (GRM) called miricorilant. The treatment involves various approaches such as ameliorating, reducing, or reversing the effects of weight gain caused by antipsychotic medications. The administration of miricorilant aims to reduce the amount and rate of weight gain, with potential weight loss observed in patients compared to their pre-treatment weight.

Furthermore, the patent claims highlight the effectiveness of miricorilant in reducing body weight, ALT or AST liver enzyme levels, plasma insulin, and insulin resistance by at least 10% when administered concomitantly with antipsychotic medication. The treatment is designed to provide significant improvements in weight-related parameters, with some claims suggesting a reduction of 20% or more in these factors compared to pre-treatment levels or average weight gain in subjects not receiving the GRM. The method involves oral administration of miricorilant and offers a promising approach to managing antipsychotic-induced weight gain in patients at risk or currently experiencing this side effect.

To know more about GlobalData’s detailed insights on Corcept Therapeutics, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies